Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

dbSNP Short Genetic Variations

Welcome to the Reference SNP (rs) Report

All alleles are reported in the Forward orientation. Click on the Variant Details tab for details on Genomic Placement, Gene, and Amino Acid changes. HGVS names are in the HGVS tab.

Reference SNP (rs) Report

This page reports data for a single dbSNP Reference SNP variation (RefSNP or rs) from the new redesigned dbSNP build.
Top of the page reports a concise summary for the rs, with more specific details included in the corresponding tabs below.
All alleles are reported in the Forward orientation. Use the Genomic View to inspect the nucleotides flanking the variant, and its neighbors.
For more information see Help documentation.

rs12248560

Current Build 157

Released September 3, 2024

Organism
Homo sapiens
Position
chr10:94761900 (GRCh38.p14) Help

The anchor position for this RefSNP. Includes all nucleotides potentially affected by this change, thus it can differ from HGVS, which is right-shifted. See here for details.

Alleles
C>A / C>T
Variation Type
SNV Single Nucleotide Variation
Frequency
T=0.196037 (51889/264690, TOPMED)
T=0.199616 (29726/148916, GnomAD_genomes)
T=0.01009 (781/77438, 38KJPN) (+ 18 more)
T=0.22229 (4199/18890, ALFA)
T=0.0109 (79/7232, Korea4K)
T=0.1593 (1020/6404, 1000G_30X)
T=0.1532 (767/5008, 1000G)
T=0.2600 (1165/4480, Estonian)
T=0.2089 (805/3854, ALSPAC)
T=0.2317 (859/3708, TWINSUK)
T=0.0082 (24/2922, KOREAN)
T=0.0104 (19/1832, Korea1K)
T=0.237 (237/998, GoNL)
T=0.016 (13/790, PRJEB37584)
T=0.185 (111/600, NorthernSweden)
T=0.179 (59/330, HapMap)
T=0.204 (44/216, Qatari)
T=0.005 (1/216, Vietnamese)
C=0.447 (51/114, SGDP_PRJ)
T=0.25 (10/40, GENOME_DK)
C=0.31 (5/16, Siberian)
Clinical Significance
Reported in ClinVar
Gene : Consequence
CYP2C19 : 2KB Upstream Variant
Publications
125 citations
Genomic View
See rs on genome

ALFA Allele Frequency
The ALFA project provide aggregate allele frequency from dbGaP. More information is available on the project page including descriptions, data access, and terms of use.

Release Version: 20231103111315
Population Group Sample Size Ref Allele Alt Allele Ref HMOZ Alt HMOZ HTRZ HWEP
Total Global 18890 C=0.77771 T=0.22229 0.606564 0.051138 0.342298 1
European Sub 14286 C=0.76865 T=0.23135 0.590928 0.053619 0.355453 0
African Sub 2946 C=0.7736 T=0.2264 0.602851 0.055669 0.34148 1
African Others Sub 114 C=0.789 T=0.211 0.614035 0.035088 0.350877 0
African American Sub 2832 C=0.7730 T=0.2270 0.602401 0.056497 0.341102 1
Asian Sub 112 C=0.982 T=0.018 0.964286 0.0 0.035714 0
East Asian Sub 86 C=0.99 T=0.01 0.976744 0.0 0.023256 0
Other Asian Sub 26 C=0.96 T=0.04 0.923077 0.0 0.076923 0
Latin American 1 Sub 146 C=0.836 T=0.164 0.684932 0.013699 0.30137 0
Latin American 2 Sub 610 C=0.897 T=0.103 0.803279 0.009836 0.186885 0
South Asian Sub 98 C=0.93 T=0.07 0.857143 0.0 0.142857 0
Other Sub 692 C=0.811 T=0.189 0.66185 0.040462 0.297688 0


Help

Frequency tab displays a table of the reference and alternate allele frequencies reported by various studies and populations. Table lines, where Population="Global" refer to the entire study population, whereas lines, where Group="Sub", refer to a study-specific population subgroupings (i.e. AFR, CAU, etc.), if available. Frequency for the alternate allele (Alt Allele) is a ratio of samples observed-to-total, where the numerator (observed samples) is the number of chromosomes in the study with the minor allele present (found in "Sample size", where Group="Sub"), and the denominator (total samples) is the total number of all chromosomes in the study for the variant (found in "Sample size", where Group="Study-wide" and Population="Global").

Download
Study Population Group Sample Size Ref Allele Alt Allele
TopMed Global Study-wide 264690 C=0.803963 T=0.196037
gnomAD v4 - Genomes Global Study-wide 148916 C=0.800384 T=0.199616
gnomAD v4 - Genomes European Sub 78454 C=0.78469 T=0.21531
gnomAD v4 - Genomes African Sub 41430 C=0.77888 T=0.22112
gnomAD v4 - Genomes American Sub 15276 C=0.86705 T=0.13295
gnomAD v4 - Genomes East Asian Sub 5174 C=0.9905 T=0.0095
gnomAD v4 - Genomes South Asian Sub 4820 C=0.8371 T=0.1629
gnomAD v4 - Genomes Ashkenazi Jewish Sub 3468 C=0.7866 T=0.2134
gnomAD v4 - Genomes Middle Eastern sub 294 C=0.769 T=0.231
38KJPN JAPANESE Study-wide 77438 C=0.98991 T=0.01009
Allele Frequency Aggregator Total Global 18890 C=0.77771 T=0.22229
Allele Frequency Aggregator European Sub 14286 C=0.76865 T=0.23135
Allele Frequency Aggregator African Sub 2946 C=0.7736 T=0.2264
Allele Frequency Aggregator Other Sub 692 C=0.811 T=0.189
Allele Frequency Aggregator Latin American 2 Sub 610 C=0.897 T=0.103
Allele Frequency Aggregator Latin American 1 Sub 146 C=0.836 T=0.164
Allele Frequency Aggregator Asian Sub 112 C=0.982 T=0.018
Allele Frequency Aggregator South Asian Sub 98 C=0.93 T=0.07
Korean Genome Project 4K KOREAN Study-wide 7232 C=0.9891 T=0.0109
1000Genomes_30X Global Study-wide 6404 C=0.8407 T=0.1593
1000Genomes_30X African Sub 1786 C=0.7637 T=0.2363
1000Genomes_30X Europe Sub 1266 C=0.7757 T=0.2243
1000Genomes_30X South Asian Sub 1202 C=0.8519 T=0.1481
1000Genomes_30X East Asian Sub 1170 C=0.9846 T=0.0154
1000Genomes_30X American Sub 980 C=0.880 T=0.120
1000Genomes Global Study-wide 5008 C=0.8468 T=0.1532
1000Genomes African Sub 1322 C=0.7648 T=0.2352
1000Genomes East Asian Sub 1008 C=0.9851 T=0.0149
1000Genomes Europe Sub 1006 C=0.7763 T=0.2237
1000Genomes South Asian Sub 978 C=0.864 T=0.136
1000Genomes American Sub 694 C=0.880 T=0.120
Genetic variation in the Estonian population Estonian Study-wide 4480 C=0.7400 T=0.2600
The Avon Longitudinal Study of Parents and Children PARENT AND CHILD COHORT Study-wide 3854 C=0.7911 T=0.2089
UK 10K study - Twins TWIN COHORT Study-wide 3708 C=0.7683 T=0.2317
KOREAN population from KRGDB KOREAN Study-wide 2922 C=0.9918 T=0.0082
Korean Genome Project KOREAN Study-wide 1832 C=0.9896 T=0.0104
Genome of the Netherlands Release 5 Genome of the Netherlands Study-wide 998 C=0.763 T=0.237
CNV burdens in cranial meningiomas Global Study-wide 790 C=0.984 T=0.016
CNV burdens in cranial meningiomas CRM Sub 790 C=0.984 T=0.016
Northern Sweden ACPOP Study-wide 600 C=0.815 T=0.185
HapMap Global Study-wide 330 C=0.821 T=0.179
HapMap African Sub 120 C=0.725 T=0.275
HapMap American Sub 120 C=0.783 T=0.217
HapMap Asian Sub 90 C=1.00 T=0.00
Qatari Global Study-wide 216 C=0.796 T=0.204
A Vietnamese Genetic Variation Database Global Study-wide 216 C=0.995 T=0.005
SGDP_PRJ Global Study-wide 114 C=0.447 T=0.553
The Danish reference pan genome Danish Study-wide 40 C=0.75 T=0.25
Siberian Global Study-wide 16 C=0.31 T=0.69
Help

Variant Details tab shows known variant placements on genomic sequences: chromosomes (NC_), RefSeqGene, pseudogenes or genomic regions (NG_), and in a separate table: on transcripts (NM_) and protein sequences (NP_). The corresponding transcript and protein locations are listed in adjacent lines, along with molecular consequences from Sequence Ontology. When no protein placement is available, only the transcript is listed. Column "Codon[Amino acid]" shows the actual base change in the format of "Reference > Alternate" allele, including the nucleotide codon change in transcripts, and the amino acid change in proteins, respectively, allowing for known ribosomal slippage sites. To view nucleotides adjacent to the variant use the Genomic View at the bottom of the page - zoom into the sequence until the nucleotides around the variant become visible.

Genomic Placements
Sequence name Change
GRCh38.p14 chr 10 NC_000010.11:g.94761900C>A
GRCh38.p14 chr 10 NC_000010.11:g.94761900C>T
GRCh37.p13 chr 10 NC_000010.10:g.96521657C>A
GRCh37.p13 chr 10 NC_000010.10:g.96521657C>T
CYP2C19 RefSeqGene (LRG_584) NG_008384.3:g.4220C>A
CYP2C19 RefSeqGene (LRG_584) NG_008384.3:g.4220C>T
LOC110599570 genomic region NG_055436.1:g.1260C>A
LOC110599570 genomic region NG_055436.1:g.1260C>T
Gene: CYP2C19, cytochrome P450 family 2 subfamily C member 19 (plus strand) : 2KB Upstream Variant
Molecule type Change Amino acid[Codon] SO Term
CYP2C19 transcript NM_000769.4:c. N/A Upstream Transcript Variant
Help

Clinical Significance tab shows a list of clinical significance entries from ClinVar associated with the variation, per allele. Click on the RCV accession (i.e. RCV000001615.2) or Allele ID (i.e. 12274) to access full ClinVar report.

Allele: T (allele ID: 47956 )
ClinVar Accession Disease Names Clinical Significance
RCV000326411.15 not provided Benign,Other
RCV000782438.10 CYP2C19: increased function Drug-Response
RCV000782443.10 Clopidogrel response Drug-Response
RCV000782446.11 Clopidogrel response Drug-Response
RCV000782447.11 Clopidogrel response Drug-Response
RCV000782451.10 Clopidogrel response Drug-Response
RCV000782454.10 Clopidogrel response Drug-Response
RCV000782459.11 Clopidogrel response Drug-Response
RCV000782460.10 Clopidogrel response Drug-Response
RCV000782461.10 Clopidogrel response Drug-Response
RCV000782462.12 Clopidogrel response Drug-Response
RCV000782463.11 Clopidogrel response Drug-Response
RCV000782492.10 Citalopram response Drug-Response
RCV000782493.10 Escitalopram response Drug-Response
RCV000782505.11 Escitalopram response Drug-Response
RCV000782506.11 Citalopram response Drug-Response
RCV000782507.11 Escitalopram response Drug-Response
RCV000782508.11 Citalopram response Drug-Response
RCV000782509.11 Escitalopram response Drug-Response
RCV000782514.11 Citalopram response Drug-Response
RCV000782515.11 Escitalopram response Drug-Response
RCV000782524.11 Citalopram response Drug-Response
RCV000782525.11 Escitalopram response Drug-Response
RCV000782529.10 Escitalopram response Drug-Response
RCV000782534.10 Citalopram response Drug-Response
RCV000782535.10 Escitalopram response Drug-Response
RCV000782536.10 Citalopram response Drug-Response
RCV000782537.10 Escitalopram response Drug-Response
RCV000782544.11 Citalopram response Drug-Response
RCV000782548.11 Citalopram response Drug-Response
RCV000782549.11 Escitalopram response Drug-Response
RCV000782553.11 Escitalopram response Drug-Response
RCV000782575.11 Citalopram response Drug-Response
RCV000782576.11 Escitalopram response Drug-Response
RCV000782600.11 Citalopram response Drug-Response
RCV000782658.10 Escitalopram response Drug-Response
RCV000782659.10 Citalopram response Drug-Response
RCV000782660.10 Escitalopram response Drug-Response
RCV000782661.10 Citalopram response Drug-Response
RCV000782662.10 Escitalopram response Drug-Response
RCV000782663.10 Citalopram response Drug-Response
RCV000782664.10 Escitalopram response Drug-Response
RCV000782713.10 Citalopram response Drug-Response
RCV000782714.10 Escitalopram response Drug-Response
RCV000782724.10 Citalopram response Drug-Response
RCV000782726.10 Citalopram response Drug-Response
RCV000782727.10 Escitalopram response Drug-Response
RCV000782728.10 Citalopram response Drug-Response
RCV000782729.10 Escitalopram response Drug-Response
RCV000782730.10 Citalopram response Drug-Response
RCV000782731.10 Escitalopram response Drug-Response
RCV000782732.11 Citalopram response Drug-Response
RCV000782733.10 Escitalopram response Drug-Response
RCV000782792.11 Escitalopram response Drug-Response
RCV000782857.11 Citalopram response Drug-Response
RCV000782858.11 Escitalopram response Drug-Response
RCV000782859.11 Citalopram response Drug-Response
RCV000782860.11 Escitalopram response Drug-Response
RCV000782861.11 Citalopram response Drug-Response
RCV000782862.11 Escitalopram response Drug-Response
RCV000782863.11 Citalopram response Drug-Response
RCV000782864.11 Escitalopram response Drug-Response
RCV000782992.10 Citalopram response Drug-Response
RCV000782993.10 Escitalopram response Drug-Response
RCV000782994.10 Citalopram response Drug-Response
RCV000782995.10 Escitalopram response Drug-Response
RCV000782996.10 Citalopram response Drug-Response
RCV000782997.10 Escitalopram response Drug-Response
RCV000782998.10 Citalopram response Drug-Response
RCV000782999.10 Escitalopram response Drug-Response
RCV000783000.10 Citalopram response Drug-Response
RCV000783049.11 Escitalopram response Drug-Response
RCV000783050.11 Citalopram response Drug-Response
RCV000783051.11 Escitalopram response Drug-Response
RCV000783052.11 Citalopram response Drug-Response
RCV000783053.11 Escitalopram response Drug-Response
RCV000783054.11 Citalopram response Drug-Response
RCV000783055.11 Escitalopram response Drug-Response
RCV000783056.11 Citalopram response Drug-Response
RCV000783071.10 Sertraline response Drug-Response
RCV000783077.11 Sertraline response Drug-Response
RCV000783078.11 Sertraline response Drug-Response
RCV000783079.11 Sertraline response Drug-Response
RCV000783087.11 Sertraline response Drug-Response
RCV000783090.10 Sertraline response Drug-Response
RCV000783091.10 Sertraline response Drug-Response
RCV000783091.10 Sertraline response Drug-Response
RCV000783092.10 Sertraline response Drug-Response
RCV000783093.10 Sertraline response Drug-Response
RCV000783097.11 Sertraline response Drug-Response
RCV000783101.11 Sertraline response Drug-Response
RCV000783112.11 Sertraline response Drug-Response
RCV000783122.11 Sertraline response Drug-Response
RCV000783123.11 Sertraline response Drug-Response
RCV000783131.11 Sertraline response Drug-Response
RCV000783171.10 Sertraline response Drug-Response
RCV000783187.10 Sertraline response Drug-Response
RCV000783188.10 Sertraline response Drug-Response
RCV000783189.10 Sertraline response Drug-Response
RCV000783190.10 Sertraline response Drug-Response
RCV000783191.10 Sertraline response Drug-Response
RCV000783223.11 Sertraline response Drug-Response
RCV000783254.11 Sertraline response Drug-Response
RCV000783255.11 Sertraline response Drug-Response
RCV000783256.11 Sertraline response Drug-Response
RCV000783257.11 Sertraline response Drug-Response
RCV000783258.11 Sertraline response Drug-Response
RCV000783259.11 Sertraline response Drug-Response
RCV000783260.11 Sertraline response Drug-Response
RCV000783325.10 Sertraline response Drug-Response
RCV000783326.10 Sertraline response Drug-Response
RCV000783372.11 Voriconazole response Drug-Response
RCV000783384.11 Voriconazole response Drug-Response
RCV000783401.11 Voriconazole response Drug-Response
RCV000783402.11 Voriconazole response Drug-Response
RCV000783403.11 Voriconazole response Drug-Response
RCV000783404.11 Voriconazole response Drug-Response
RCV000783405.11 Voriconazole response Drug-Response
RCV000783406.11 Voriconazole response Drug-Response
RCV000783472.10 Voriconazole response Drug-Response
RCV000783473.10 Voriconazole response Drug-Response
RCV000783512.11 Voriconazole response Drug-Response
RCV000783513.11 Voriconazole response Drug-Response
RCV000783523.10 Voriconazole response Drug-Response
RCV000783524.10 Voriconazole response Drug-Response
RCV000783525.10 Voriconazole response Drug-Response
RCV000783526.10 Voriconazole response Drug-Response
RCV000783526.10 Voriconazole response Drug-Response
RCV000783527.10 Voriconazole response Drug-Response
RCV000783528.10 Voriconazole response Drug-Response
RCV000783530.11 Voriconazole response Drug-Response
RCV000783536.11 Voriconazole response Drug-Response
RCV000783557.11 Voriconazole response Drug-Response
RCV000783558.11 Voriconazole response Drug-Response
RCV000783559.11 Voriconazole response Drug-Response
RCV000783568.11 Voriconazole response Drug-Response
RCV000783587.10 Voriconazole response Drug-Response
RCV000783588.10 Voriconazole response Drug-Response
RCV000783617.10 Voriconazole response Drug-Response
RCV000783622.10 Voriconazole response Drug-Response
RCV000783630.10 Voriconazole response Drug-Response
RCV000783631.11 Voriconazole response Drug-Response
RCV000783632.10 Voriconazole response Drug-Response
RCV000783633.10 Voriconazole response Drug-Response
RCV000783634.10 Voriconazole response Drug-Response
RCV000783635.10 Voriconazole response Drug-Response
RCV000783649.11 CYP2C19: no function Drug-Response
RCV000783666.11 Clopidogrel response Drug-Response
RCV000783667.11 Clopidogrel response Drug-Response
RCV000783668.10 Clopidogrel response Drug-Response
RCV000783669.10 Clopidogrel response Drug-Response
RCV000783669.10 Clopidogrel response Drug-Response
RCV000783670.11 Clopidogrel response Drug-Response
RCV000783671.11 Clopidogrel response Drug-Response
RCV000783676.10 Clopidogrel response Drug-Response
RCV000783682.10 Clopidogrel response Drug-Response
RCV000783683.10 Clopidogrel response Drug-Response
RCV000783735.11 Citalopram response Drug-Response
RCV000783759.10 Citalopram response Drug-Response
RCV000783760.10 Escitalopram response Drug-Response
RCV000783761.10 Citalopram response Drug-Response
RCV000783762.10 Escitalopram response Drug-Response
RCV000783763.10 Citalopram response Drug-Response
RCV000783763.10 Citalopram response Drug-Response
RCV000783764.10 Escitalopram response Drug-Response
RCV000783764.10 Escitalopram response Drug-Response
RCV000783765.10 Citalopram response Drug-Response
RCV000783766.10 Escitalopram response Drug-Response
RCV000783767.10 Citalopram response Drug-Response
RCV000783768.11 Escitalopram response Drug-Response
RCV000783783.11 Citalopram response Drug-Response
RCV000783787.11 Citalopram response Drug-Response
RCV000783788.11 Escitalopram response Drug-Response
RCV000783821.11 Citalopram response Drug-Response
RCV000783822.11 Escitalopram response Drug-Response
RCV000783826.11 Escitalopram response Drug-Response
RCV000783827.11 Citalopram response Drug-Response
RCV000783828.11 Escitalopram response Drug-Response
RCV000783829.11 Citalopram response Drug-Response
RCV000783830.11 Escitalopram response Drug-Response
RCV000783848.11 Citalopram response Drug-Response
RCV000783849.11 Escitalopram response Drug-Response
RCV000783888.10 Citalopram response Drug-Response
RCV000783889.10 Escitalopram response Drug-Response
RCV000783890.10 Citalopram response Drug-Response
RCV000783891.10 Escitalopram response Drug-Response
RCV000783892.10 Citalopram response Drug-Response
RCV000783926.10 Citalopram response Drug-Response
RCV000783927.10 Escitalopram response Drug-Response
RCV000783950.10 Escitalopram response Drug-Response
RCV000783958.11 Escitalopram response Drug-Response
RCV000783959.10 Citalopram response Drug-Response
RCV000783960.10 Escitalopram response Drug-Response
RCV000783961.10 Citalopram response Drug-Response
RCV000783962.10 Escitalopram response Drug-Response
RCV000783963.10 Citalopram response Drug-Response
RCV000783964.10 Escitalopram response Drug-Response
RCV000783965.10 Citalopram response Drug-Response
RCV000783985.12 Citalopram response Drug-Response
RCV000783986.12 Escitalopram response Drug-Response
RCV000784024.11 Citalopram response Drug-Response
RCV000784049.11 Citalopram response Drug-Response
RCV000784050.11 Escitalopram response Drug-Response
RCV000784083.11 Citalopram response Drug-Response
RCV000784084.11 Escitalopram response Drug-Response
RCV000784085.11 Citalopram response Drug-Response
RCV000784086.11 Escitalopram response Drug-Response
RCV000784087.11 Citalopram response Drug-Response
RCV000784088.11 Escitalopram response Drug-Response
RCV000784089.11 Citalopram response Drug-Response
RCV000784090.11 Escitalopram response Drug-Response
RCV000784222.10 Escitalopram response Drug-Response
RCV000784223.10 Citalopram response Drug-Response
RCV000784224.10 Escitalopram response Drug-Response
RCV000784225.10 Citalopram response Drug-Response
RCV000784226.10 Escitalopram response Drug-Response
RCV000784227.10 Citalopram response Drug-Response
RCV000784228.10 Escitalopram response Drug-Response
RCV000784229.10 Citalopram response Drug-Response
RCV000784230.10 Escitalopram response Drug-Response
RCV000784231.10 Citalopram response Drug-Response
RCV000784232.10 Escitalopram response Drug-Response
RCV000784285.11 Citalopram response Drug-Response
RCV000784286.11 Escitalopram response Drug-Response
RCV000784287.11 Citalopram response Drug-Response
RCV000784288.11 Escitalopram response Drug-Response
RCV000784315.11 Sertraline response Drug-Response
RCV000784322.10 Sertraline response Drug-Response
RCV000784325.10 Sertraline response Drug-Response
RCV000784326.10 Sertraline response Drug-Response
RCV000784332.11 Sertraline response Drug-Response
RCV000784336.11 Sertraline response Drug-Response
RCV000784353.11 Sertraline response Drug-Response
RCV000784359.11 Sertraline response Drug-Response
RCV000784386.10 Sertraline response Drug-Response
RCV000784387.10 Sertraline response Drug-Response
RCV000784388.10 Sertraline response Drug-Response
RCV000784389.10 Sertraline response Drug-Response
RCV000784390.10 Sertraline response Drug-Response
RCV000784391.10 Sertraline response Drug-Response
RCV000784415.10 Sertraline response Drug-Response
RCV000784421.10 Sertraline response Drug-Response
RCV000784422.10 Sertraline response Drug-Response
RCV000784423.10 Sertraline response Drug-Response
RCV000784424.11 Sertraline response Drug-Response
RCV000784433.12 Sertraline response Drug-Response
RCV000784435.11 Sertraline response Drug-Response
RCV000784436.11 Sertraline response Drug-Response
RCV000784437.11 Sertraline response Drug-Response
RCV000784438.11 Sertraline response Drug-Response
RCV000784439.11 Sertraline response Drug-Response
RCV000784440.11 Sertraline response Drug-Response
RCV000784472.11 Sertraline response Drug-Response
RCV000784489.11 Sertraline response Drug-Response
RCV000784549.12 Voriconazole response Drug-Response
RCV000784557.10 Sertraline response Drug-Response
RCV000784558.10 Sertraline response Drug-Response
RCV000784559.10 Sertraline response Drug-Response
RCV000784560.10 Sertraline response Drug-Response
RCV000784561.10 Sertraline response Drug-Response
RCV000784562.10 Sertraline response Drug-Response
RCV000784563.10 Sertraline response Drug-Response
RCV000784564.10 Sertraline response Drug-Response
RCV000784638.11 Voriconazole response Drug-Response
RCV000784639.11 Voriconazole response Drug-Response
RCV000784705.10 Voriconazole response Drug-Response
RCV000784706.10 Voriconazole response Drug-Response
RCV000784707.10 Voriconazole response Drug-Response
RCV000784708.10 Voriconazole response Drug-Response
RCV000784709.10 Voriconazole response Drug-Response
RCV000784710.10 Voriconazole response Drug-Response
RCV000784711.10 Voriconazole response Drug-Response
RCV000784712.10 Voriconazole response Drug-Response
RCV000784737.10 Voriconazole response Drug-Response
RCV000784745.11 Voriconazole response Drug-Response
RCV000784752.11 Voriconazole response Drug-Response
RCV000784753.11 Voriconazole response Drug-Response
RCV000784759.10 Voriconazole response Drug-Response
RCV000784763.11 Voriconazole response Drug-Response
RCV000784773.11 Voriconazole response Drug-Response
RCV000784779.11 Voriconazole response Drug-Response
RCV000784789.11 Voriconazole response Drug-Response
RCV000784809.10 Voriconazole response Drug-Response
RCV000784810.10 Voriconazole response Drug-Response
RCV000784811.10 Voriconazole response Drug-Response
RCV000784812.10 Voriconazole response Drug-Response
RCV000784851.10 Voriconazole response Drug-Response
RCV000784856.10 Voriconazole response Drug-Response
RCV000784857.10 Voriconazole response Drug-Response
RCV000784868.11 Voriconazole response Drug-Response
RCV000784869.11 Voriconazole response Drug-Response
RCV000784870.11 Voriconazole response Drug-Response
RCV000784871.11 Voriconazole response Drug-Response
RCV000784872.11 Voriconazole response Drug-Response
RCV000784873.11 Voriconazole response Drug-Response
Help

Aliases tab displays HGVS names representing the variant placements and allele changes on genomic, transcript and protein sequences, per allele. HGVS name is an expression for reporting sequence accession and version, sequence type, position, and allele change. The column "Note" can have two values: "diff" means that there is a difference between the reference allele (variation interval) at the placement reported in HGVS name and the reference alleles reported in other HGVS names, and "rev" means that the sequence of this variation interval at the placement reported in HGVS name is in reverse orientation to the sequence(s) of this variation in other HGVS names not labeled as "rev".

Placement C= A T
GRCh38.p14 chr 10 NC_000010.11:g.94761900= NC_000010.11:g.94761900C>A NC_000010.11:g.94761900C>T
GRCh37.p13 chr 10 NC_000010.10:g.96521657= NC_000010.10:g.96521657C>A NC_000010.10:g.96521657C>T
CYP2C19 RefSeqGene (LRG_584) NG_008384.3:g.4220= NG_008384.3:g.4220C>A NG_008384.3:g.4220C>T
LOC110599570 genomic region NG_055436.1:g.1260= NG_055436.1:g.1260C>A NG_055436.1:g.1260C>T
Help

Submissions tab displays variations originally submitted to dbSNP, now supporting this RefSNP cluster (rs). We display Submitter handle, Submission identifier, Date and Build number, when the submission appeared for the first time. Direct submissions to dbSNP have Submission ID in the form of an ss-prefixed number (ss#). Other supporting variations are listed in the table without ss#.

86 SubSNP, 21 Frequency, 290 ClinVar submissions
No Submitter Submission ID Date (Build)
1 SC_SNP ss18627820 Feb 28, 2004 (120)
2 SSAHASNP ss20629041 Apr 05, 2004 (121)
3 PERLEGEN ss24554293 Sep 20, 2004 (123)
4 EGP_SNPS ss28531395 Dec 02, 2004 (126)
5 ABI ss39719499 Mar 10, 2006 (126)
6 HUMANGENOME_JCVI ss97675639 Feb 06, 2009 (130)
7 1000GENOMES ss113672527 Jan 25, 2009 (130)
8 ENSEMBL ss137888305 Dec 01, 2009 (131)
9 JIPGENE ss158145861 Dec 01, 2009 (131)
10 JIPGENE ss158145862 Dec 01, 2009 (131)
11 JIPGENE ss158145863 Dec 01, 2009 (131)
12 COMPLETE_GENOMICS ss170776165 Jul 04, 2010 (132)
13 1000GENOMES ss224884168 Jul 14, 2010 (132)
14 1000GENOMES ss235292619 Jul 15, 2010 (132)
15 GMI ss280732303 May 04, 2012 (137)
16 GMI ss286243779 Apr 25, 2013 (138)
17 PJP ss290909204 May 09, 2011 (134)
18 TISHKOFF ss562142848 Apr 25, 2013 (138)
19 SSMP ss657183816 Apr 25, 2013 (138)
20 EVA-GONL ss987804334 Aug 21, 2014 (142)
21 JMKIDD_LAB ss1077215281 Aug 21, 2014 (142)
22 1000GENOMES ss1338622991 Aug 21, 2014 (142)
23 DDI ss1426411098 Apr 01, 2015 (144)
24 CLINVAR ss1457608700 Nov 23, 2014 (142)
25 EVA_GENOME_DK ss1575296670 Apr 01, 2015 (144)
26 EVA_DECODE ss1597477658 Apr 01, 2015 (144)
27 EVA_UK10K_ALSPAC ss1625195760 Apr 01, 2015 (144)
28 EVA_UK10K_TWINSUK ss1668189793 Apr 01, 2015 (144)
29 WEILL_CORNELL_DGM ss1931170324 Feb 12, 2016 (147)
30 JJLAB ss2026313586 Sep 14, 2016 (149)
31 CLINVAR ss2137495309 Feb 23, 2017 (149)
32 MYSEQ1_SNP ss2137544432 Nov 01, 2024 (157)
33 EVA ss2137544462 Nov 01, 2024 (157)
34 USC_VALOUEV ss2154590234 Nov 08, 2017 (151)
35 HUMAN_LONGEVITY ss2177147096 Dec 20, 2016 (150)
36 GRF ss2698842972 Nov 08, 2017 (151)
37 GNOMAD ss2892126623 Nov 08, 2017 (151)
38 SWEGEN ss3006965807 Nov 08, 2017 (151)
39 BIOINF_KMB_FNS_UNIBA ss3026946906 Nov 08, 2017 (151)
40 CSHL ss3349261213 Nov 08, 2017 (151)
41 URBANLAB ss3649441543 Oct 12, 2018 (152)
42 EGCUT_WGS ss3674377968 Jul 13, 2019 (153)
43 EVA_DECODE ss3690461668 Jul 13, 2019 (153)
44 ACPOP ss3737585473 Jul 13, 2019 (153)
45 EVA ss3748468190 Jul 13, 2019 (153)
46 KHV_HUMAN_GENOMES ss3813834340 Jul 13, 2019 (153)
47 EVA ss3832276807 Apr 26, 2020 (154)
48 SGDP_PRJ ss3874827278 Apr 26, 2020 (154)
49 KRGDB ss3922955442 Apr 26, 2020 (154)
50 KOGIC ss3968458147 Apr 26, 2020 (154)
51 EVA ss3984639028 Apr 26, 2021 (155)
52 TOPMED ss4862622612 Apr 26, 2021 (155)
53 TOMMO_GENOMICS ss6114200526 Nov 01, 2024 (157)
54 EVA ss6253826032 Nov 01, 2024 (157)
55 EVA ss6307409869 Nov 01, 2024 (157)
56 EVA ss6322395594 Nov 01, 2024 (157)
57 EVA ss6326442641 Nov 01, 2024 (157)
58 EVA ss6332060631 Nov 01, 2024 (157)
59 YEGNASUBRAMANIAN_LAB ss6343187231 Nov 01, 2024 (157)
60 EVA ss6349787529 Nov 01, 2024 (157)
61 EVA ss6349997713 Nov 01, 2024 (157)
62 KOGIC ss6382288653 Nov 01, 2024 (157)
63 GNOMAD ss6859874352 Nov 01, 2024 (157)
64 TOMMO_GENOMICS ss8198968530 Nov 01, 2024 (157)
65 EVA ss8237481891 Nov 01, 2024 (157)
66 EVA ss8237481892 Nov 01, 2024 (157)
67 EVA ss8237481893 Nov 01, 2024 (157)
68 1000G_HIGH_COVERAGE ss8285087471 Nov 01, 2024 (157)
69 TRAN_CS_UWATERLOO ss8314429322 Nov 01, 2024 (157)
70 EVA ss8395322415 Nov 01, 2024 (157)
71 HUGCELL_USP ss8480547542 Nov 01, 2024 (157)
72 EVA ss8510129323 Nov 01, 2024 (157)
73 1000G_HIGH_COVERAGE ss8579564134 Nov 01, 2024 (157)
74 SANFORD_IMAGENETICS ss8624255696 Nov 01, 2024 (157)
75 SANFORD_IMAGENETICS ss8649885623 Nov 01, 2024 (157)
76 TOMMO_GENOMICS ss8745186048 Nov 01, 2024 (157)
77 EVA ss8799403694 Nov 01, 2024 (157)
78 YY_MCH ss8811792280 Nov 01, 2024 (157)
79 EVA ss8824807337 Nov 01, 2024 (157)
80 EVA ss8847378107 Nov 01, 2024 (157)
81 EVA ss8847605615 Nov 01, 2024 (157)
82 EVA ss8849697092 Nov 01, 2024 (157)
83 EVA ss8880085382 Nov 01, 2024 (157)
84 EVA ss8941172158 Nov 01, 2024 (157)
85 EVA ss8981728040 Nov 01, 2024 (157)
86 EVA ss8982151818 Nov 01, 2024 (157)
87 1000Genomes NC_000010.10 - 96521657 Oct 12, 2018 (152)
88 1000Genomes_30X NC_000010.11 - 94761900 Nov 01, 2024 (157)
89 The Avon Longitudinal Study of Parents and Children NC_000010.10 - 96521657 Oct 12, 2018 (152)
90 Genetic variation in the Estonian population NC_000010.10 - 96521657 Oct 12, 2018 (152)
91 The Danish reference pan genome NC_000010.10 - 96521657 Apr 26, 2020 (154)
92 gnomAD v4 - Genomes NC_000010.11 - 94761900 Nov 01, 2024 (157)
93 Genome of the Netherlands Release 5 NC_000010.10 - 96521657 Apr 26, 2020 (154)
94 HapMap NC_000010.11 - 94761900 Apr 26, 2020 (154)
95 KOREAN population from KRGDB NC_000010.10 - 96521657 Apr 26, 2020 (154)
96 Korean Genome Project NC_000010.11 - 94761900 Apr 26, 2020 (154)
97 Korean Genome Project 4K NC_000010.11 - 94761900 Nov 01, 2024 (157)
98 Northern Sweden NC_000010.10 - 96521657 Jul 13, 2019 (153)
99 CNV burdens in cranial meningiomas NC_000010.10 - 96521657 Apr 26, 2021 (155)
100 Qatari NC_000010.10 - 96521657 Apr 26, 2020 (154)
101 SGDP_PRJ NC_000010.10 - 96521657 Apr 26, 2020 (154)
102 Siberian NC_000010.10 - 96521657 Apr 26, 2020 (154)
103 38KJPN NC_000010.11 - 94761900 Nov 01, 2024 (157)
104 TopMed NC_000010.11 - 94761900 Apr 26, 2021 (155)
105 UK 10K study - Twins NC_000010.10 - 96521657 Oct 12, 2018 (152)
106 A Vietnamese Genetic Variation Database NC_000010.10 - 96521657 Jul 13, 2019 (153)
107 ALFA NC_000010.11 - 94761900 Nov 01, 2024 (157)
108 ClinVar RCV000326411.15 Nov 01, 2024 (157)
109 ClinVar RCV000782438.10 Nov 01, 2024 (157)
110 ClinVar RCV000782443.10 Nov 01, 2024 (157)
111 ClinVar RCV000782446.11 Nov 01, 2024 (157)
112 ClinVar RCV000782447.11 Nov 01, 2024 (157)
113 ClinVar RCV000782451.10 Nov 01, 2024 (157)
114 ClinVar RCV000782454.10 Nov 01, 2024 (157)
115 ClinVar RCV000782459.11 Nov 01, 2024 (157)
116 ClinVar RCV000782460.10 Nov 01, 2024 (157)
117 ClinVar RCV000782461.10 Nov 01, 2024 (157)
118 ClinVar RCV000782462.12 Nov 01, 2024 (157)
119 ClinVar RCV000782463.11 Nov 01, 2024 (157)
120 ClinVar RCV000782492.10 Nov 01, 2024 (157)
121 ClinVar RCV000782493.10 Nov 01, 2024 (157)
122 ClinVar RCV000782505.11 Nov 01, 2024 (157)
123 ClinVar RCV000782506.11 Nov 01, 2024 (157)
124 ClinVar RCV000782507.11 Nov 01, 2024 (157)
125 ClinVar RCV000782508.11 Nov 01, 2024 (157)
126 ClinVar RCV000782509.11 Nov 01, 2024 (157)
127 ClinVar RCV000782514.11 Nov 01, 2024 (157)
128 ClinVar RCV000782515.11 Nov 01, 2024 (157)
129 ClinVar RCV000782524.11 Nov 01, 2024 (157)
130 ClinVar RCV000782525.11 Nov 01, 2024 (157)
131 ClinVar RCV000782529.10 Nov 01, 2024 (157)
132 ClinVar RCV000782534.10 Nov 01, 2024 (157)
133 ClinVar RCV000782535.10 Nov 01, 2024 (157)
134 ClinVar RCV000782536.10 Nov 01, 2024 (157)
135 ClinVar RCV000782537.10 Nov 01, 2024 (157)
136 ClinVar RCV000782544.11 Nov 01, 2024 (157)
137 ClinVar RCV000782548.11 Nov 01, 2024 (157)
138 ClinVar RCV000782549.11 Nov 01, 2024 (157)
139 ClinVar RCV000782553.11 Nov 01, 2024 (157)
140 ClinVar RCV000782575.11 Nov 01, 2024 (157)
141 ClinVar RCV000782576.11 Nov 01, 2024 (157)
142 ClinVar RCV000782600.11 Nov 01, 2024 (157)
143 ClinVar RCV000782658.10 Nov 01, 2024 (157)
144 ClinVar RCV000782659.10 Nov 01, 2024 (157)
145 ClinVar RCV000782660.10 Nov 01, 2024 (157)
146 ClinVar RCV000782661.10 Nov 01, 2024 (157)
147 ClinVar RCV000782662.10 Nov 01, 2024 (157)
148 ClinVar RCV000782663.10 Nov 01, 2024 (157)
149 ClinVar RCV000782664.10 Nov 01, 2024 (157)
150 ClinVar RCV000782713.10 Nov 01, 2024 (157)
151 ClinVar RCV000782714.10 Nov 01, 2024 (157)
152 ClinVar RCV000782724.10 Nov 01, 2024 (157)
153 ClinVar RCV000782726.10 Nov 01, 2024 (157)
154 ClinVar RCV000782727.10 Nov 01, 2024 (157)
155 ClinVar RCV000782728.10 Nov 01, 2024 (157)
156 ClinVar RCV000782729.10 Nov 01, 2024 (157)
157 ClinVar RCV000782730.10 Nov 01, 2024 (157)
158 ClinVar RCV000782731.10 Nov 01, 2024 (157)
159 ClinVar RCV000782732.11 Nov 01, 2024 (157)
160 ClinVar RCV000782733.10 Nov 01, 2024 (157)
161 ClinVar RCV000782792.11 Nov 01, 2024 (157)
162 ClinVar RCV000782857.11 Nov 01, 2024 (157)
163 ClinVar RCV000782858.11 Nov 01, 2024 (157)
164 ClinVar RCV000782859.11 Nov 01, 2024 (157)
165 ClinVar RCV000782860.11 Nov 01, 2024 (157)
166 ClinVar RCV000782861.11 Nov 01, 2024 (157)
167 ClinVar RCV000782862.11 Nov 01, 2024 (157)
168 ClinVar RCV000782863.11 Nov 01, 2024 (157)
169 ClinVar RCV000782864.11 Nov 01, 2024 (157)
170 ClinVar RCV000782992.10 Nov 01, 2024 (157)
171 ClinVar RCV000782993.10 Nov 01, 2024 (157)
172 ClinVar RCV000782994.10 Nov 01, 2024 (157)
173 ClinVar RCV000782995.10 Nov 01, 2024 (157)
174 ClinVar RCV000782996.10 Nov 01, 2024 (157)
175 ClinVar RCV000782997.10 Nov 01, 2024 (157)
176 ClinVar RCV000782998.10 Nov 01, 2024 (157)
177 ClinVar RCV000782999.10 Nov 01, 2024 (157)
178 ClinVar RCV000783000.10 Nov 01, 2024 (157)
179 ClinVar RCV000783049.11 Nov 01, 2024 (157)
180 ClinVar RCV000783050.11 Nov 01, 2024 (157)
181 ClinVar RCV000783051.11 Nov 01, 2024 (157)
182 ClinVar RCV000783052.11 Nov 01, 2024 (157)
183 ClinVar RCV000783053.11 Nov 01, 2024 (157)
184 ClinVar RCV000783054.11 Nov 01, 2024 (157)
185 ClinVar RCV000783055.11 Nov 01, 2024 (157)
186 ClinVar RCV000783056.11 Nov 01, 2024 (157)
187 ClinVar RCV000783071.10 Nov 01, 2024 (157)
188 ClinVar RCV000783077.11 Nov 01, 2024 (157)
189 ClinVar RCV000783078.11 Nov 01, 2024 (157)
190 ClinVar RCV000783079.11 Nov 01, 2024 (157)
191 ClinVar RCV000783087.11 Nov 01, 2024 (157)
192 ClinVar RCV000783090.10 Nov 01, 2024 (157)
193 ClinVar RCV000783091.10 Nov 01, 2024 (157)
194 ClinVar RCV000783092.10 Nov 01, 2024 (157)
195 ClinVar RCV000783093.10 Nov 01, 2024 (157)
196 ClinVar RCV000783097.11 Nov 01, 2024 (157)
197 ClinVar RCV000783101.11 Nov 01, 2024 (157)
198 ClinVar RCV000783112.11 Nov 01, 2024 (157)
199 ClinVar RCV000783122.11 Nov 01, 2024 (157)
200 ClinVar RCV000783123.11 Nov 01, 2024 (157)
201 ClinVar RCV000783131.11 Nov 01, 2024 (157)
202 ClinVar RCV000783171.10 Nov 01, 2024 (157)
203 ClinVar RCV000783187.10 Nov 01, 2024 (157)
204 ClinVar RCV000783188.10 Nov 01, 2024 (157)
205 ClinVar RCV000783189.10 Nov 01, 2024 (157)
206 ClinVar RCV000783190.10 Nov 01, 2024 (157)
207 ClinVar RCV000783191.10 Nov 01, 2024 (157)
208 ClinVar RCV000783223.11 Nov 01, 2024 (157)
209 ClinVar RCV000783254.11 Nov 01, 2024 (157)
210 ClinVar RCV000783255.11 Nov 01, 2024 (157)
211 ClinVar RCV000783256.11 Nov 01, 2024 (157)
212 ClinVar RCV000783257.11 Nov 01, 2024 (157)
213 ClinVar RCV000783258.11 Nov 01, 2024 (157)
214 ClinVar RCV000783259.11 Nov 01, 2024 (157)
215 ClinVar RCV000783260.11 Nov 01, 2024 (157)
216 ClinVar RCV000783325.10 Nov 01, 2024 (157)
217 ClinVar RCV000783326.10 Nov 01, 2024 (157)
218 ClinVar RCV000783372.11 Nov 01, 2024 (157)
219 ClinVar RCV000783384.11 Nov 01, 2024 (157)
220 ClinVar RCV000783401.11 Nov 01, 2024 (157)
221 ClinVar RCV000783402.11 Nov 01, 2024 (157)
222 ClinVar RCV000783403.11 Nov 01, 2024 (157)
223 ClinVar RCV000783404.11 Nov 01, 2024 (157)
224 ClinVar RCV000783405.11 Nov 01, 2024 (157)
225 ClinVar RCV000783406.11 Nov 01, 2024 (157)
226 ClinVar RCV000783472.10 Nov 01, 2024 (157)
227 ClinVar RCV000783473.10 Nov 01, 2024 (157)
228 ClinVar RCV000783512.11 Nov 01, 2024 (157)
229 ClinVar RCV000783513.11 Nov 01, 2024 (157)
230 ClinVar RCV000783523.10 Nov 01, 2024 (157)
231 ClinVar RCV000783524.10 Nov 01, 2024 (157)
232 ClinVar RCV000783525.10 Nov 01, 2024 (157)
233 ClinVar RCV000783526.10 Nov 01, 2024 (157)
234 ClinVar RCV000783527.10 Nov 01, 2024 (157)
235 ClinVar RCV000783528.10 Nov 01, 2024 (157)
236 ClinVar RCV000783530.11 Nov 01, 2024 (157)
237 ClinVar RCV000783536.11 Nov 01, 2024 (157)
238 ClinVar RCV000783557.11 Nov 01, 2024 (157)
239 ClinVar RCV000783558.11 Nov 01, 2024 (157)
240 ClinVar RCV000783559.11 Nov 01, 2024 (157)
241 ClinVar RCV000783568.11 Nov 01, 2024 (157)
242 ClinVar RCV000783587.10 Nov 01, 2024 (157)
243 ClinVar RCV000783588.10 Nov 01, 2024 (157)
244 ClinVar RCV000783617.10 Nov 01, 2024 (157)
245 ClinVar RCV000783622.10 Nov 01, 2024 (157)
246 ClinVar RCV000783630.10 Nov 01, 2024 (157)
247 ClinVar RCV000783631.11 Nov 01, 2024 (157)
248 ClinVar RCV000783632.10 Nov 01, 2024 (157)
249 ClinVar RCV000783633.10 Nov 01, 2024 (157)
250 ClinVar RCV000783634.10 Nov 01, 2024 (157)
251 ClinVar RCV000783635.10 Nov 01, 2024 (157)
252 ClinVar RCV000783649.11 Nov 01, 2024 (157)
253 ClinVar RCV000783666.11 Nov 01, 2024 (157)
254 ClinVar RCV000783667.11 Nov 01, 2024 (157)
255 ClinVar RCV000783668.10 Nov 01, 2024 (157)
256 ClinVar RCV000783669.10 Nov 01, 2024 (157)
257 ClinVar RCV000783670.11 Nov 01, 2024 (157)
258 ClinVar RCV000783671.11 Nov 01, 2024 (157)
259 ClinVar RCV000783676.10 Nov 01, 2024 (157)
260 ClinVar RCV000783682.10 Nov 01, 2024 (157)
261 ClinVar RCV000783683.10 Nov 01, 2024 (157)
262 ClinVar RCV000783735.11 Nov 01, 2024 (157)
263 ClinVar RCV000783759.10 Nov 01, 2024 (157)
264 ClinVar RCV000783760.10 Nov 01, 2024 (157)
265 ClinVar RCV000783761.10 Nov 01, 2024 (157)
266 ClinVar RCV000783762.10 Nov 01, 2024 (157)
267 ClinVar RCV000783763.10 Nov 01, 2024 (157)
268 ClinVar RCV000783764.10 Nov 01, 2024 (157)
269 ClinVar RCV000783765.10 Nov 01, 2024 (157)
270 ClinVar RCV000783766.10 Nov 01, 2024 (157)
271 ClinVar RCV000783767.10 Nov 01, 2024 (157)
272 ClinVar RCV000783768.11 Nov 01, 2024 (157)
273 ClinVar RCV000783783.11 Nov 01, 2024 (157)
274 ClinVar RCV000783787.11 Nov 01, 2024 (157)
275 ClinVar RCV000783788.11 Nov 01, 2024 (157)
276 ClinVar RCV000783821.11 Nov 01, 2024 (157)
277 ClinVar RCV000783822.11 Nov 01, 2024 (157)
278 ClinVar RCV000783826.11 Nov 01, 2024 (157)
279 ClinVar RCV000783827.11 Nov 01, 2024 (157)
280 ClinVar RCV000783828.11 Nov 01, 2024 (157)
281 ClinVar RCV000783829.11 Nov 01, 2024 (157)
282 ClinVar RCV000783830.11 Nov 01, 2024 (157)
283 ClinVar RCV000783848.11 Nov 01, 2024 (157)
284 ClinVar RCV000783849.11 Nov 01, 2024 (157)
285 ClinVar RCV000783888.10 Nov 01, 2024 (157)
286 ClinVar RCV000783889.10 Nov 01, 2024 (157)
287 ClinVar RCV000783890.10 Nov 01, 2024 (157)
288 ClinVar RCV000783891.10 Nov 01, 2024 (157)
289 ClinVar RCV000783892.10 Nov 01, 2024 (157)
290 ClinVar RCV000783926.10 Nov 01, 2024 (157)
291 ClinVar RCV000783927.10 Nov 01, 2024 (157)
292 ClinVar RCV000783950.10 Nov 01, 2024 (157)
293 ClinVar RCV000783958.11 Nov 01, 2024 (157)
294 ClinVar RCV000783959.10 Nov 01, 2024 (157)
295 ClinVar RCV000783960.10 Nov 01, 2024 (157)
296 ClinVar RCV000783961.10 Nov 01, 2024 (157)
297 ClinVar RCV000783962.10 Nov 01, 2024 (157)
298 ClinVar RCV000783963.10 Nov 01, 2024 (157)
299 ClinVar RCV000783964.10 Nov 01, 2024 (157)
300 ClinVar RCV000783965.10 Nov 01, 2024 (157)
301 ClinVar RCV000783985.12 Nov 01, 2024 (157)
302 ClinVar RCV000783986.12 Nov 01, 2024 (157)
303 ClinVar RCV000784024.11 Nov 01, 2024 (157)
304 ClinVar RCV000784049.11 Nov 01, 2024 (157)
305 ClinVar RCV000784050.11 Nov 01, 2024 (157)
306 ClinVar RCV000784083.11 Nov 01, 2024 (157)
307 ClinVar RCV000784084.11 Nov 01, 2024 (157)
308 ClinVar RCV000784085.11 Nov 01, 2024 (157)
309 ClinVar RCV000784086.11 Nov 01, 2024 (157)
310 ClinVar RCV000784087.11 Nov 01, 2024 (157)
311 ClinVar RCV000784088.11 Nov 01, 2024 (157)
312 ClinVar RCV000784089.11 Nov 01, 2024 (157)
313 ClinVar RCV000784090.11 Nov 01, 2024 (157)
314 ClinVar RCV000784222.10 Nov 01, 2024 (157)
315 ClinVar RCV000784223.10 Nov 01, 2024 (157)
316 ClinVar RCV000784224.10 Nov 01, 2024 (157)
317 ClinVar RCV000784225.10 Nov 01, 2024 (157)
318 ClinVar RCV000784226.10 Nov 01, 2024 (157)
319 ClinVar RCV000784227.10 Nov 01, 2024 (157)
320 ClinVar RCV000784228.10 Nov 01, 2024 (157)
321 ClinVar RCV000784229.10 Nov 01, 2024 (157)
322 ClinVar RCV000784230.10 Nov 01, 2024 (157)
323 ClinVar RCV000784231.10 Nov 01, 2024 (157)
324 ClinVar RCV000784232.10 Nov 01, 2024 (157)
325 ClinVar RCV000784285.11 Nov 01, 2024 (157)
326 ClinVar RCV000784286.11 Nov 01, 2024 (157)
327 ClinVar RCV000784287.11 Nov 01, 2024 (157)
328 ClinVar RCV000784288.11 Nov 01, 2024 (157)
329 ClinVar RCV000784315.11 Nov 01, 2024 (157)
330 ClinVar RCV000784322.10 Nov 01, 2024 (157)
331 ClinVar RCV000784325.10 Nov 01, 2024 (157)
332 ClinVar RCV000784326.10 Nov 01, 2024 (157)
333 ClinVar RCV000784332.11 Nov 01, 2024 (157)
334 ClinVar RCV000784336.11 Nov 01, 2024 (157)
335 ClinVar RCV000784353.11 Nov 01, 2024 (157)
336 ClinVar RCV000784359.11 Nov 01, 2024 (157)
337 ClinVar RCV000784386.10 Nov 01, 2024 (157)
338 ClinVar RCV000784387.10 Nov 01, 2024 (157)
339 ClinVar RCV000784388.10 Nov 01, 2024 (157)
340 ClinVar RCV000784389.10 Nov 01, 2024 (157)
341 ClinVar RCV000784390.10 Nov 01, 2024 (157)
342 ClinVar RCV000784391.10 Nov 01, 2024 (157)
343 ClinVar RCV000784415.10 Nov 01, 2024 (157)
344 ClinVar RCV000784421.10 Nov 01, 2024 (157)
345 ClinVar RCV000784422.10 Nov 01, 2024 (157)
346 ClinVar RCV000784423.10 Nov 01, 2024 (157)
347 ClinVar RCV000784424.11 Nov 01, 2024 (157)
348 ClinVar RCV000784433.12 Nov 01, 2024 (157)
349 ClinVar RCV000784435.11 Nov 01, 2024 (157)
350 ClinVar RCV000784436.11 Nov 01, 2024 (157)
351 ClinVar RCV000784437.11 Nov 01, 2024 (157)
352 ClinVar RCV000784438.11 Nov 01, 2024 (157)
353 ClinVar RCV000784439.11 Nov 01, 2024 (157)
354 ClinVar RCV000784440.11 Nov 01, 2024 (157)
355 ClinVar RCV000784472.11 Nov 01, 2024 (157)
356 ClinVar RCV000784489.11 Nov 01, 2024 (157)
357 ClinVar RCV000784549.12 Nov 01, 2024 (157)
358 ClinVar RCV000784557.10 Nov 01, 2024 (157)
359 ClinVar RCV000784558.10 Nov 01, 2024 (157)
360 ClinVar RCV000784559.10 Nov 01, 2024 (157)
361 ClinVar RCV000784560.10 Nov 01, 2024 (157)
362 ClinVar RCV000784561.10 Nov 01, 2024 (157)
363 ClinVar RCV000784562.10 Nov 01, 2024 (157)
364 ClinVar RCV000784563.10 Nov 01, 2024 (157)
365 ClinVar RCV000784564.10 Nov 01, 2024 (157)
366 ClinVar RCV000784638.11 Nov 01, 2024 (157)
367 ClinVar RCV000784639.11 Nov 01, 2024 (157)
368 ClinVar RCV000784705.10 Nov 01, 2024 (157)
369 ClinVar RCV000784706.10 Nov 01, 2024 (157)
370 ClinVar RCV000784707.10 Nov 01, 2024 (157)
371 ClinVar RCV000784708.10 Nov 01, 2024 (157)
372 ClinVar RCV000784709.10 Nov 01, 2024 (157)
373 ClinVar RCV000784710.10 Nov 01, 2024 (157)
374 ClinVar RCV000784711.10 Nov 01, 2024 (157)
375 ClinVar RCV000784712.10 Nov 01, 2024 (157)
376 ClinVar RCV000784737.10 Nov 01, 2024 (157)
377 ClinVar RCV000784745.11 Nov 01, 2024 (157)
378 ClinVar RCV000784752.11 Nov 01, 2024 (157)
379 ClinVar RCV000784753.11 Nov 01, 2024 (157)
380 ClinVar RCV000784759.10 Nov 01, 2024 (157)
381 ClinVar RCV000784763.11 Nov 01, 2024 (157)
382 ClinVar RCV000784773.11 Nov 01, 2024 (157)
383 ClinVar RCV000784779.11 Nov 01, 2024 (157)
384 ClinVar RCV000784789.11 Nov 01, 2024 (157)
385 ClinVar RCV000784809.10 Nov 01, 2024 (157)
386 ClinVar RCV000784810.10 Nov 01, 2024 (157)
387 ClinVar RCV000784811.10 Nov 01, 2024 (157)
388 ClinVar RCV000784812.10 Nov 01, 2024 (157)
389 ClinVar RCV000784851.10 Nov 01, 2024 (157)
390 ClinVar RCV000784856.10 Nov 01, 2024 (157)
391 ClinVar RCV000784857.10 Nov 01, 2024 (157)
392 ClinVar RCV000784868.11 Nov 01, 2024 (157)
393 ClinVar RCV000784869.11 Nov 01, 2024 (157)
394 ClinVar RCV000784870.11 Nov 01, 2024 (157)
395 ClinVar RCV000784871.11 Nov 01, 2024 (157)
396 ClinVar RCV000784872.11 Nov 01, 2024 (157)
397 ClinVar RCV000784873.11 Nov 01, 2024 (157)
Help

History tab displays RefSNPs (Associated ID) from previous builds (Build) that now support the current RefSNP, and the dates, when the history was updated for each Associated ID (History Updated).

Associated ID History Updated (Build)
rs17442305 Oct 08, 2004 (123)
rs17879736 Mar 10, 2006 (126)
rs117093607 Aug 16, 2010 (132)
Added to this RefSNP Cluster:
Submission IDs Observation SPDI Canonical SPDI Source RSIDs
ss8624255696 NC_000010.10:96521656:C:A NC_000010.11:94761899:C:A (self)
ss2137495309 NC_000010.11:94761899:C:A NC_000010.11:94761899:C:A (self)
ss158145862 NT_030059.13:47326120:C:A NC_000010.11:94761899:C:A (self)
ss113672527, ss170776165, ss280732303, ss286243779, ss290909204, ss1597477658 NC_000010.9:96511646:C:T NC_000010.11:94761899:C:T (self)
51054405, 28345299, 20116216, 2282719, 12639199, 30132836, 10870338, 188493, 13212254, 26844258, 7106588, 28345299, 6294330, ss224884168, ss235292619, ss562142848, ss657183816, ss987804334, ss1077215281, ss1338622991, ss1426411098, ss1575296670, ss1625195760, ss1668189793, ss1931170324, ss2026313586, ss2154590234, ss2698842972, ss2892126623, ss3006965807, ss3349261213, ss3674377968, ss3737585473, ss3748468190, ss3832276807, ss3874827278, ss3922955442, ss3984639028, ss6253826032, ss6307409869, ss6322395594, ss6326442641, ss6332060631, ss6343187231, ss6349787529, ss8198968530, ss8237481891, ss8237481892, ss8237481893, ss8395322415, ss8510129323, ss8624255696, ss8649885623, ss8799403694, ss8824807337, ss8847378107, ss8847605615, ss8941172158, ss8981728040, ss8982151818 NC_000010.10:96521656:C:T NC_000010.11:94761899:C:T (self)
RCV000326411.15, RCV000782438.10, RCV000782443.10, RCV000782446.11, RCV000782447.11, RCV000782451.10, RCV000782454.10, RCV000782459.11, RCV000782460.10, RCV000782461.10, RCV000782462.12, RCV000782463.11, RCV000782492.10, RCV000782493.10, RCV000782505.11, RCV000782506.11, RCV000782507.11, RCV000782508.11, RCV000782509.11, RCV000782514.11, RCV000782515.11, RCV000782524.11, RCV000782525.11, RCV000782529.10, RCV000782534.10, RCV000782535.10, RCV000782536.10, RCV000782537.10, RCV000782544.11, RCV000782548.11, RCV000782549.11, RCV000782553.11, RCV000782575.11, RCV000782576.11, RCV000782600.11, RCV000782658.10, RCV000782659.10, RCV000782660.10, RCV000782661.10, RCV000782662.10, RCV000782663.10, RCV000782664.10, RCV000782713.10, RCV000782714.10, RCV000782724.10, RCV000782726.10, RCV000782727.10, RCV000782728.10, RCV000782729.10, RCV000782730.10, RCV000782731.10, RCV000782732.11, RCV000782733.10, RCV000782792.11, RCV000782857.11, RCV000782858.11, RCV000782859.11, RCV000782860.11, RCV000782861.11, RCV000782862.11, RCV000782863.11, RCV000782864.11, RCV000782992.10, RCV000782993.10, RCV000782994.10, RCV000782995.10, RCV000782996.10, RCV000782997.10, RCV000782998.10, RCV000782999.10, RCV000783000.10, RCV000783049.11, RCV000783050.11, RCV000783051.11, RCV000783052.11, RCV000783053.11, RCV000783054.11, RCV000783055.11, RCV000783056.11, RCV000783071.10, RCV000783077.11, RCV000783078.11, RCV000783079.11, RCV000783087.11, RCV000783090.10, RCV000783091.10, RCV000783092.10, RCV000783093.10, RCV000783097.11, RCV000783101.11, RCV000783112.11, RCV000783122.11, RCV000783123.11, RCV000783131.11, RCV000783171.10, RCV000783187.10, RCV000783188.10, RCV000783189.10, RCV000783190.10, RCV000783191.10, RCV000783223.11, RCV000783254.11, RCV000783255.11, RCV000783256.11, RCV000783257.11, RCV000783258.11, RCV000783259.11, RCV000783260.11, RCV000783325.10, RCV000783326.10, RCV000783372.11, RCV000783384.11, RCV000783401.11, RCV000783402.11, RCV000783403.11, RCV000783404.11, RCV000783405.11, RCV000783406.11, RCV000783472.10, RCV000783473.10, RCV000783512.11, RCV000783513.11, RCV000783523.10, RCV000783524.10, RCV000783525.10, RCV000783526.10, RCV000783527.10, RCV000783528.10, RCV000783530.11, RCV000783536.11, RCV000783557.11, RCV000783558.11, RCV000783559.11, RCV000783568.11, RCV000783587.10, RCV000783588.10, RCV000783617.10, RCV000783622.10, RCV000783630.10, RCV000783631.11, RCV000783632.10, RCV000783633.10, RCV000783634.10, RCV000783635.10, RCV000783649.11, RCV000783666.11, RCV000783667.11, RCV000783668.10, RCV000783669.10, RCV000783670.11, RCV000783671.11, RCV000783676.10, RCV000783682.10, RCV000783683.10, RCV000783735.11, RCV000783759.10, RCV000783760.10, RCV000783761.10, RCV000783762.10, RCV000783763.10, RCV000783764.10, RCV000783765.10, RCV000783766.10, RCV000783767.10, RCV000783768.11, RCV000783783.11, RCV000783787.11, RCV000783788.11, RCV000783821.11, RCV000783822.11, RCV000783826.11, RCV000783827.11, RCV000783828.11, RCV000783829.11, RCV000783830.11, RCV000783848.11, RCV000783849.11, RCV000783888.10, RCV000783889.10, RCV000783890.10, RCV000783891.10, RCV000783892.10, RCV000783926.10, RCV000783927.10, RCV000783950.10, RCV000783958.11, RCV000783959.10, RCV000783960.10, RCV000783961.10, RCV000783962.10, RCV000783963.10, RCV000783964.10, RCV000783965.10, RCV000783985.12, RCV000783986.12, RCV000784024.11, RCV000784049.11, RCV000784050.11, RCV000784083.11, RCV000784084.11, RCV000784085.11, RCV000784086.11, RCV000784087.11, RCV000784088.11, RCV000784089.11, RCV000784090.11, RCV000784222.10, RCV000784223.10, RCV000784224.10, RCV000784225.10, RCV000784226.10, RCV000784227.10, RCV000784228.10, RCV000784229.10, RCV000784230.10, RCV000784231.10, RCV000784232.10, RCV000784285.11, RCV000784286.11, RCV000784287.11, RCV000784288.11, RCV000784315.11, RCV000784322.10, RCV000784325.10, RCV000784326.10, RCV000784332.11, RCV000784336.11, RCV000784353.11, RCV000784359.11, RCV000784386.10, RCV000784387.10, RCV000784388.10, RCV000784389.10, RCV000784390.10, RCV000784391.10, RCV000784415.10, RCV000784421.10, RCV000784422.10, RCV000784423.10, RCV000784424.11, RCV000784433.12, RCV000784435.11, RCV000784436.11, RCV000784437.11, RCV000784438.11, RCV000784439.11, RCV000784440.11, RCV000784472.11, RCV000784489.11, RCV000784549.12, RCV000784557.10, RCV000784558.10, RCV000784559.10, RCV000784560.10, RCV000784561.10, RCV000784562.10, RCV000784563.10, RCV000784564.10, RCV000784638.11, RCV000784639.11, RCV000784705.10, RCV000784706.10, RCV000784707.10, RCV000784708.10, RCV000784709.10, RCV000784710.10, RCV000784711.10, RCV000784712.10, RCV000784737.10, RCV000784745.11, RCV000784752.11, RCV000784753.11, RCV000784759.10, RCV000784763.11, RCV000784773.11, RCV000784779.11, RCV000784789.11, RCV000784809.10, RCV000784810.10, RCV000784811.10, RCV000784812.10, RCV000784851.10, RCV000784856.10, RCV000784857.10, RCV000784868.11, RCV000784869.11, RCV000784870.11, RCV000784871.11, RCV000784872.11, RCV000784873.11, 67090069, 387010091, 468169, 24836148, 32140551, 131576346, 78168267, 2625147327, ss1457608700, ss2137544432, ss2137544462, ss2177147096, ss3026946906, ss3649441543, ss3690461668, ss3813834340, ss3968458147, ss4862622612, ss6114200526, ss6349997713, ss6382288653, ss6859874352, ss8285087471, ss8314429322, ss8480547542, ss8579564134, ss8745186048, ss8811792280, ss8849697092, ss8880085382 NC_000010.11:94761899:C:T NC_000010.11:94761899:C:T (self)
ss18627820, ss20629041 NT_030059.11:15270182:C:T NC_000010.11:94761899:C:T (self)
ss24554293, ss28531395, ss39719499, ss97675639, ss137888305, ss158145861, ss158145863 NT_030059.13:47326120:C:T NC_000010.11:94761899:C:T (self)
Help

Publications tab displays PubMed articles citing the variation as a listing of PMID, Title, Author, Year, Journal, ordered by Year, descending.

125 citations for rs12248560
PMID Title Author Year Journal
17048007 Association of warfarin dose with genes involved in its action and metabolism. Wadelius M et al. 2007 Human genetics
17625515 Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Rudberg I et al. 2008 Clinical pharmacology and therapeutics
18521743 CYP2C19*17 is associated with decreased breast cancer risk. Justenhoven C et al. 2009 Breast cancer research and treatment
19136640 Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test. Desta Z et al. 2009 The Journal of pharmacology and experimental therapeutics
19463375 The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. Gladding P et al. 2008 JACC. Cardiovascular interventions
19706858 Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. Shuldiner AR et al. 2009 JAMA
20083681 Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Sibbing D et al. 2010 Circulation
20492469 Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. Sibbing D et al. 2010 Journal of thrombosis and haemostasis
20531370 Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. de Vos A et al. 2011 The pharmacogenomics journal
20801498 Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Wallentin L et al. 2010 Lancet (London, England)
20826260 Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Tiroch KA et al. 2010 American heart journal
20847277 Genotyping of DNA samples isolated from formalin-fixed paraffin-embedded tissues using preamplification. Baak-Pablo R et al. 2010 The Journal of molecular diagnostics
20921971 Mapping genes that predict treatment outcome in admixed populations. Baye TM et al. 2010 The pharmacogenomics journal
21071160 Analysis of 50 SNPs in CYP2D6, CYP2C19, CYP2C9, CYP3A4 and CYP1A2 by MALDI-TOF mass spectrometry in Chinese Han population. Shi Y et al. 2011 Forensic science international
21172166 Pharmacogenetics of antidepressant response. Porcelli S et al. 2011 Journal of psychiatry & neuroscience
21192344 CYP2C19 variation and citalopram response. Mrazek DA et al. 2011 Pharmacogenetics and genomics
21247447 CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. Santos PC et al. 2011 BMC medical genetics
21358751 Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. Scott SA et al. 2012 The pharmacogenomics journal
21392617 The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. Gurbel PA et al. 2011 American heart journal
21480951 Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Lim JS et al. 2011 British journal of clinical pharmacology
21497341 High-density fine-mapping of a chromosome 10q26 linkage peak suggests association between endometriosis and variants close to CYP2C19. Painter JN et al. 2011 Fertility and sterility
21546862 PharmGKB summary: citalopram pharmacokinetics pathway. Sangkuhl K et al. 2011 Pharmacogenetics and genomics
21712189 Analysis of pharmacogenetic traits in two distinct South African populations. Ikediobi O et al. 2011 Human genomics
21716271 Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Scott SA et al. 2011 Clinical pharmacology and therapeutics
21816733 Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. Bauer T et al. 2011 BMJ (Clinical research ed.)
21918509 Pharmacogenomics: application to the management of cardiovascular disease. Johnson JA et al. 2011 Clinical pharmacology and therapeutics
22028352 Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. Cayla G et al. 2011 JAMA
22190063 Predicting clopidogrel response using DNA samples linked to an electronic health record. Delaney JT et al. 2012 Clinical pharmacology and therapeutics
22228204 The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Harmsze AM et al. 2012 Pharmacogenetics and genomics
22462746 CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects. Chan MY et al. 2012 Pharmacogenomics
22491019 Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. Martis S et al. 2013 The pharmacogenomics journal
22704413 Relationship between cytochrome P450 2C19*17 genotype distribution, platelet aggregation and bleeding risk in patients with blood stasis syndrome of coronary artery disease treated with clopidogrel. Dai ZL et al. 2012 Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
22723959 Paraoxonase-1 is not a major determinant of stent thrombosis in a Taiwanese population. Chen DY et al. 2012 PloS one
22784880 Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis. Wiese MD et al. 2012 Arthritis research & therapy
22879966 Systematic testing of literature reported genetic variation associated with coronary restenosis: results of the GENDER Study. Verschuren JJ et al. 2012 PloS one
22955794 Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population. Subraja K et al. 2013 European journal of clinical pharmacology
22990067 Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China. Wu H et al. 2012 Pharmacogenetics and genomics
22992668 Pharmacogenomics knowledge for personalized medicine. Whirl-Carrillo M et al. 2012 Clinical pharmacology and therapeutics
23133420 Pharmacogenomic Diversity among Brazilians: Influence of Ancestry, Self-Reported Color, and Geographical Origin. Suarez-Kurtz G et al. 2012 Frontiers in pharmacology
23226154 Polymorphisms of Phase I and Phase II Enzymes and Breast Cancer Risk. Justenhoven C et al. 2012 Frontiers in genetics
23364775 Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes. Carlquist JF et al. 2013 Thrombosis and haemostasis
23697979 Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation? Perry CG et al. 2013 Journal of human genetics
23698643 Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Scott SA et al. 2013 Clinical pharmacology and therapeutics
23726091 Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients. Zhang L et al. 2013 Thrombosis research
23797323 Pharmacogenomics of anti-platelet and anti-coagulation therapy. Fisch AS et al. 2013 Current cardiology reports
23809542 The CYP2C19*17 variant is not independently associated with clopidogrel response. Lewis JP et al. 2013 Journal of thrombosis and haemostasis
23810503 Comparison of high-resolution melting analysis, TaqMan Allelic discrimination assay, and sanger sequencing for Clopidogrel efficacy genotyping in routine molecular diagnostics. Zhang L et al. 2013 The Journal of molecular diagnostics
23922007 Impact of the CYP2C19*17 polymorphism on the clinical outcome of clopidogrel therapy in Asian patients undergoing percutaneous coronary intervention. Park MW et al. 2013 Pharmacogenetics and genomics
24019397 CYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable angina. Kim HS et al. 2013 Circulation. Cardiovascular genetics
24519754 CYP2C19 genotype-phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity. Burns KE et al. 2014 Cancer chemotherapy and pharmacology
24762860 Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction. Cresci S et al. 2014 Circulation. Cardiovascular genetics
24796765 Common variants in the CYP2C19 gene are associated with susceptibility to endometriosis. Painter JN et al. 2014 Fertility and sterility
24944790 Screening for 392 polymorphisms in 141 pharmacogenes. Kim JY et al. 2014 Biomedical reports
25051347 Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention. Siller-Matula JM et al. 2014 PloS one
25419701 Exploring the distribution of genetic markers of pharmacogenomics relevance in Brazilian and Mexican populations. Bonifaz-Peña V et al. 2014 PloS one
25714468 A systematic approach to the reporting of medically relevant findings from whole genome sequencing. McLaughlin HM et al. 2014 BMC medical genetics
25897256 Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. Beitelshees AL et al. 2015 Pharmacogenomics and personalized medicine
26323597 Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content. Shirasaka Y et al. 2016 The pharmacogenomics journal
26757134 Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population. Khalil BM et al. 2016 Clinical and translational science
26773420 Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma. Veal GJ et al. 2016 European journal of cancer (Oxford, England
26781306 Genotype‑phenotype analysis of CYP2C19 in the Tibetan population and its potential clinical implications in drug therapy. Jin T et al. 2016 Molecular medicine reports
26785747 Polymorphisms in genes involved in the absorption, distribution, metabolism, and excretion of drugs in the Kazakhs of Kazakhstan. Iskakova AN et al. 2016 BMC genetics
26858644 Cross-Comparison of Exome Analysis, Next-Generation Sequencing of Amplicons, and the iPLEX(®) ADME PGx Panel for Pharmacogenomic Profiling. Chua EW et al. 2016 Frontiers in pharmacology
26870959 Association of PON1, P2Y12 and COX1 with Recurrent Ischemic Events in Patients with Extracranial or Intracranial Stenting. Li XQ et al. 2016 PloS one
27002825 Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with Cyclophosphamide. Audemard-Verger A et al. 2016 PloS one
27171561 Liver Function Test Abnormalities in Depressed Patients Treated with Antidepressants: A Real-World Systematic Observational Study in Psychiatric Settings. Voican CS et al. 2016 PloS one
27249515 Evidence for extensive pleiotropy among pharmacogenes. Oetjens MT et al. 2016 Pharmacogenomics
27277665 Genetic risk factors for restenosis after percutaneous coronary intervention in Kazakh population. Zholdybayeva EV et al. 2016 Human genomics
27368038 CYP2C19 loss-of-function alleles are not associated with clinical outcome of clopidogrel therapy in patients treated with newer-generation drug-eluting stents. Choi IJ et al. 2016 Medicine
27529241 The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key? Daud AN et al. 2016 International journal of molecular sciences
27636550 A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics. Mizzi C et al. 2016 PloS one
27798644 Detection of CYP2C19 Genetic Variants in Malaysian Orang Asli from Massively Parallel Sequencing Data. Ang GY et al. 2016 PloS one
28378544 Effects of CYP2C19 Genetic Polymorphisms on PK/PD Responses of Omeprazole in Korean Healthy Volunteers. Park S et al. 2017 Journal of Korean medical science
29033601 Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients. Denisenko NP et al. 2017 Pharmacogenomics and personalized medicine
29167499 A Novel Multiplex HRM Assay to Detect Clopidogrel Resistance. Zhang L et al. 2017 Scientific reports
29193749 Clinical Implementation of Pharmacogenetic Testing in a Hospital of the Spanish National Health System: Strategy and Experience Over 3 Years. Borobia AM et al. 2018 Clinical and translational science
29260275 Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel. Novkovic M et al. 2018 European journal of clinical pharmacology
29681089 Genetic variation in biotransformation enzymes, air pollution exposures, and risk of spina bifida. Padula AM et al. 2018 American journal of medical genetics. Part A
29756345 Common Polymorphisms of CYP2B6 Influence Stereoselective Bupropion Disposition. Kharasch ED et al. 2019 Clinical pharmacology and therapeutics
29950882 CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole. Denisenko NP et al. 2018 Pharmacogenomics and personalized medicine
30068618 Cohort Profile: the Predictors of Breast Cancer Recurrence (ProBe CaRE) Premenopausal Breast Cancer Cohort Study in Denmark. Collin LJ et al. 2018 BMJ open
30093869 Biological Predictors of Clozapine Response: A Systematic Review. Samanaite R et al. 2018 Frontiers in psychiatry
30135031 Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies. Fabbri C et al. 2018 European neuropsychopharmacology
30452466 Characterization of ADME genes variation in Roma and 20 populations worldwide. Škarić-Jurić T et al. 2018 PloS one
30758238 Development and Cross-Validation of High-Resolution Melting Analysis-Based Cardiovascular Pharmacogenetics Genotyping Panel. Langaee T et al. 2019 Genetic testing and molecular biomarkers
30988702 Defining the genetic profile of endometriosis. Vassilopoulou L et al. 2019 Experimental and therapeutic medicine
31019283 Secondary actionable findings identified by exome sequencing: expected impact on the organisation of care from the study of 700 consecutive tests. Thauvin-Robinet C et al. 2019 European journal of human genetics
31086207 Implications of genetic variation of common Drug Metabolizing Enzymes and ABC Transporters among the Pakistani Population. Afsar NA et al. 2019 Scientific reports
31184624 [Genetic and non-genetic factors of laboratory resistance to clopidogrel in patients with ischemic stroke]. Sychev DA et al. 2019 Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
31222084 Frequency of the CYP2C19*17 polymorphism in a Chilean population and its effect on voriconazole plasma concentration in immunocompromised children. Espinoza N et al. 2019 Scientific reports
31270413
31441095 Development and validation of T-ARMS-PCR to detect CYP2C19*17 allele. Jin C et al. 2020 Journal of clinical laboratory analysis
31617956 A pharmacogenetic risk score for the evaluation of major depression severity under treatment with antidepressants. Kanders SH et al. 2020 Drug development research
31807051 Antihypertensive Effect Of Amlodipine In Co-Administration With Omeprazole In Patients With Hypertension And Acid-Related Disorders: Cytochrome P450-Associated Aspects. Dorofeeva MN et al. 2019 Pharmacogenomics and personalized medicine
32134726 How do CYP2C19*2 and CYP2C19*17 genetic polymorphisms affect the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome? Skryabin VY et al. 2020 Drug metabolism and personalized therapy
32158254 CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban. Sychev DA et al. 2020 Pharmacogenomics and personalized medicine
32303955 Clinically relevant pharmacogenetic markers in Tatars and Balkars. Abdullaev SP et al. 2020 Molecular biology reports
32392440 The Frequency of the Minor Polymorphisms in the CYP2C19, VEGFR-2 Genes, and Clinical Outcomes in Russian and Buryat Patients with Acute Coronary Syndrome. Zelenskaya EM et al. 2020 Genetic testing and molecular biomarkers
32472697 Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. Verma SS et al. 2020 Clinical pharmacology and therapeutics
32639515 Bayesian Pathway Analysis for Complex Interactions. Baurley JW et al. 2020 American journal of epidemiology
32862511 Distribution of CYP2C19, ABCB1 and PON1 polymorphisms in Chinese Han, Hui, Uygur and Kazak patients with coronary atherosclerotic heart disease. Ma L et al. 2020 International journal of immunogenetics
33124772 Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections. Chuwongwattana S et al. 2020 Pharmacology research & perspectives
33192522 Pleiotropic Functions of Cytochrome P450 Monooxygenase-Derived Eicosanoids in Cancer. Luo Y et al. 2020 Frontiers in pharmacology
33423267 [Association of CYP2C19 and CYP3A5 gene polymorphisms with myocardial infarction]. Qi L et al. 2021 Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
33519226 Genetic Diversity of Drug-Related Genes in Native Americans of the Brazilian Amazon. Fernandes MR et al. 2021 Pharmacogenomics and personalized medicine
33569925 Gene-environment interactions between air pollution and biotransformation enzymes and risk of birth defects. Padula AM et al. 2021 Birth defects research
33580125 Preservation of epoxyeicosatrienoic acid bioavailability prevents renal allograft dysfunction and cardiovascular alterations in kidney transplant recipients. Duflot T et al. 2021 Scientific reports
33805706 SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability. Zubiaur P et al. 2021 Journal of personalized medicine
33995083 Dexketoprofen Pharmacokinetics is not Significantly Altered by Genetic Polymorphism. Mejía-Abril G et al. 2021 Frontiers in pharmacology
34382722 Profiling of warfarin pharmacokinetics-associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics-dosing algorithm. Ndadza A et al. 2021 Journal of thrombosis and haemostasis
34385834 Individualized Drugs' Selection by Evaluation of Drug Properties, Pharmacogenomics and Clinical Parameters: Performance of a Bioinformatic Tool Compared to a Clinically Established Counselling Process. Borro M et al. 2021 Pharmacogenomics and personalized medicine
34429635 Population Genetic Difference of Pharmacogenomic VIP Variants in the Tibetan Population. He C et al. 2021 Pharmacogenomics and personalized medicine
34621165 Lack of Major Involvement of Common CYP2C Gene Polymorphisms in the Risk of Developing Cross-Hypersensitivity to NSAIDs. Macías Y et al. 2021 Frontiers in pharmacology
34621706 Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform. Kim B et al. 2021 Translational and clinical pharmacology
34690761 Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin. Villapalos-García G et al. 2021 Frontiers in pharmacology
34920277 Assessment of susceptibility to phthalate and DINCH exposure through CYP and UGT single nucleotide polymorphisms. Stajnko A et al. 2022 Environment international
34949935 Genetic Polymorphisms of Very Important Pharmacogene Variants in the Blang Population from Yunnan Province in China. Wang Y et al. 2021 Pharmacogenomics and personalized medicine
34958284 Warfarin Pharmacogenomics for Precision Medicine in Real-Life Clinical Practice in Southern Africa: Harnessing 73 Variants in 29 Pharmacogenes. Muyambo S et al. 2022 Omics
35089958 Identification of pharmacogenetic variants from large scale next generation sequencing data in the Saudi population. Goljan E et al. 2022 PloS one
35235711 Evaluation of the relationship between polymorphisms in CYP2C19 and the single-dose pharmacokinetics of omeprazole in healthy Chinese volunteers: A multicenter study. Zhou S et al. 2022 Clinical and translational science
35664313 Omeprazole Treatment Failure in Gastroesophageal Reflux Disease and Genetic Variation at the CYP2C Locus. Kee PS et al. 2022 Frontiers in genetics
35761855 Pharmacogenetics of Breast Cancer Treatments: A Sub-Saharan Africa Perspective. Nthontho KC et al. 2022 Pharmacogenomics and personalized medicine
36065758 CYP2C8*3 and *4 define CYP2C8 phenotype: An approach with the substrate cinitapride. Campodónico DM et al. 2022 Clinical and translational science
36164570 Prevalence of exposure to pharmacogenetic drugs by the Saudis treated at the health care centers of the Ministry of National Guard. Alshabeeb MA et al. 2022 Saudi pharmaceutical journal
36333412 Effect of CYP2C19 polymorphisms on antidepressant prescription patterns and treatment emergent mania in bipolar disorder. Joas E et al. 2023 The pharmacogenomics journal
Help

The Flanks tab provides retrieving flanking sequences of a SNP on all molecules that have placements.

Genome context:
Select flank length:

Genomic regions, transcripts, and products
Top Help

NCBI Graphical Sequence Viewer display of the genomic region, transcripts and protein products for the reported RefSNP (rs).
Use the zoom option to view the nucleotides around the RefSNP and find other neighboring RefSNPs.
Visit Sequence Viewer for help with navigating inside the display and modifying the selection of displayed data tracks.

Software version is: 2.0.1.post825+45319f0